Marc R Dweck1, Ronan Abgral2, Maria Giovanna Trivieri3, Philip M Robson3, Nicolas Karakatsanis3, Venkatesh Mani3, Anna Palmisano3, Marc A Miller4, Anuradha Lala4, Helena L Chang5, Javier Sanz4, Johanna Contreras4, Jagat Narula4, Valentin Fuster4, Maria Padilla6, Zahi A Fayad7, Jason C Kovacic8. 1. Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York; British Heart Foundation/University Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, Scotland, United Kingdom. 2. Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Nuclear Medicine, European University of Brittany, CHRU Brest, Brest, France. 3. Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York. 4. Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York. 5. International Center for Health Outcomes and Innovation Research, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York. 6. Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. 7. Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: zahi.fayad@mssm.edu. 8. Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: jason.kovacic@mountsinai.org.
Abstract
OBJECTIVES: The purpose of this study was to explore the diagnostic usefulness of hybrid cardiac magnetic resonance (CMR) and positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) for active cardiac sarcoidosis. BACKGROUND: Active cardiac sarcoidosis (aCS) is underdiagnosed and has a high mortality. METHODS: Patients with clinical suspicion of aCS underwent hybrid CMR/PET with late gadolinium enhancement (LGE) and FDG to assess the pattern of injury and disease activity, respectively. Patients were categorized visually as magnetic resonance (MR)+PET+ (characteristic LGE aligning exactly with increased FDG uptake), MR+PET- (characteristic LGE but no increased FDG), MR-PET- (neither characteristic LGE nor increased FDG), and MR-PET+ (increased FDG uptake in absence of characteristic LGE) and further characterized as aCS+ (MR+PET+) or aCS- (MR+PET-, MR-PET-, MR-PET+). FDG uptake was quantified using maximum target-to-normal-myocardium ratio and the net uptake rate (Ki) from dynamic Patlak analysis. Receiver-operating characteristic methods were used to identify imaging biomarkers for aCS. FDG PET was assessed using computed tomography/PET in 19 control subjects with healthy myocardium. RESULTS: A total of 25 patients (12 males; 54.9 ± 9.8 years of age) were recruited prospectively; 8 were MR+PET+, suggestive of aCS; 1 was MR+PET-, consistent with inactive cardiac sarcoidosis; and 8 were MR-PET-, with no imaging evidence of cardiac sarcoidosis. Eight patients were MR-PET+ (6 with global myocardial FDG uptake, 2 with focal-on-diffuse uptake); they demonstrated distinct Ki values and hyperintense maximum standardized uptake value compared with MR+PET+ patients. Similar hyperintense patterns of global (n = 9) and focal-on-diffuse (n = 2) FDG uptake were also observed in control patients, suggesting physiological myocardial uptake. Maximum target-to-normal-myocardium ratio values were higher in the aCS+ group (p < 0.001), demonstrating an area under the curve of 0.98 on receiver-operating characteristic analysis for the detection of aCS, with an optimal maximum target-to-normal myocardium ratio threshold of 1.2 (Youden index: 0.94). CONCLUSIONS: CMR/PET imaging holds major promise for the diagnosis of aCS, providing incremental information about both the pattern of injury and disease activity in a single scan. (In Vivo Molecular Imaging [MRI] of Atherothrombotic Lesions; NCT01418313).
OBJECTIVES: The purpose of this study was to explore the diagnostic usefulness of hybrid cardiac magnetic resonance (CMR) and positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) for active cardiac sarcoidosis. BACKGROUND: Active cardiac sarcoidosis (aCS) is underdiagnosed and has a high mortality. METHODS: Patients with clinical suspicion of aCS underwent hybrid CMR/PET with late gadolinium enhancement (LGE) and FDG to assess the pattern of injury and disease activity, respectively. Patients were categorized visually as magnetic resonance (MR)+PET+ (characteristic LGE aligning exactly with increased FDG uptake), MR+PET- (characteristic LGE but no increased FDG), MR-PET- (neither characteristic LGE nor increased FDG), and MR-PET+ (increased FDG uptake in absence of characteristic LGE) and further characterized as aCS+ (MR+PET+) or aCS- (MR+PET-, MR-PET-, MR-PET+). FDG uptake was quantified using maximum target-to-normal-myocardium ratio and the net uptake rate (Ki) from dynamic Patlak analysis. Receiver-operating characteristic methods were used to identify imaging biomarkers for aCS. FDG PET was assessed using computed tomography/PET in 19 control subjects with healthy myocardium. RESULTS: A total of 25 patients (12 males; 54.9 ± 9.8 years of age) were recruited prospectively; 8 were MR+PET+, suggestive of aCS; 1 was MR+PET-, consistent with inactive cardiac sarcoidosis; and 8 were MR-PET-, with no imaging evidence of cardiac sarcoidosis. Eight patients were MR-PET+ (6 with global myocardial FDG uptake, 2 with focal-on-diffuse uptake); they demonstrated distinct Ki values and hyperintense maximum standardized uptake value compared with MR+PET+ patients. Similar hyperintense patterns of global (n = 9) and focal-on-diffuse (n = 2) FDG uptake were also observed in control patients, suggesting physiological myocardial uptake. Maximum target-to-normal-myocardium ratio values were higher in the aCS+ group (p < 0.001), demonstrating an area under the curve of 0.98 on receiver-operating characteristic analysis for the detection of aCS, with an optimal maximum target-to-normal myocardium ratio threshold of 1.2 (Youden index: 0.94). CONCLUSIONS: CMR/PET imaging holds major promise for the diagnosis of aCS, providing incremental information about both the pattern of injury and disease activity in a single scan. (In Vivo Molecular Imaging [MRI] of Atherothrombotic Lesions; NCT01418313).
Authors: Hiroshi Ohira; David H Birnie; Elena Pena; Jordan Bernick; Brian Mc Ardle; Eugene Leung; George A Wells; Keiichiro Yoshinaga; Ichizo Tsujino; Takahiro Sato; Osamu Manabe; Noriko Oyama-Manabe; Masaharu Nishimura; Nagara Tamaki; Alexander Dick; Carole Dennie; Ran Klein; Jennifer Renaud; Robert A deKemp; Terrence D Ruddy; Benjamin J W Chow; Ross Davies; Renee Hessian; Peter Liu; Rob S B Beanlands; Pablo B Nery Journal: Eur J Nucl Med Mol Imaging Date: 2015-09-11 Impact factor: 9.236
Authors: Ron Blankstein; Michael Osborne; Masanao Naya; Alfonso Waller; Chun K Kim; Venkatesh L Murthy; Pedram Kazemian; Raymond Y Kwong; Michifumi Tokuda; Hicham Skali; Robert Padera; Jon Hainer; William G Stevenson; Sharmila Dorbala; Marcelo F Di Carli Journal: J Am Coll Cardiol Date: 2013-10-16 Impact factor: 24.094
Authors: Nikhil V Joshi; Alex T Vesey; Michelle C Williams; Anoop S V Shah; Patrick A Calvert; Felicity H M Craighead; Su Ern Yeoh; William Wallace; Donald Salter; Alison M Fletcher; Edwin J R van Beek; Andrew D Flapan; Neal G Uren; Miles W H Behan; Nicholas L M Cruden; Nicholas L Mills; Keith A A Fox; James H F Rudd; Marc R Dweck; David E Newby Journal: Lancet Date: 2013-11-11 Impact factor: 79.321
Authors: Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Saenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld Journal: J Interv Card Electrophysiol Date: 2020-10 Impact factor: 1.900
Authors: Arman Rahmim; Martin A Lodge; Nicolas A Karakatsanis; Vladimir Y Panin; Yun Zhou; Alan McMillan; Steve Cho; Habib Zaidi; Michael E Casey; Richard L Wahl Journal: Eur J Nucl Med Mol Imaging Date: 2018-09-29 Impact factor: 9.236
Authors: Kalie Y Kebed; Spencer V Carter; Erin Flatley; R Parker Ward; Joshua D Moss; Daniel E Appelbaum; Amita Singh; Roberto M Lang; Roderick Tung; Amit R Patel Journal: Int J Cardiovasc Imaging Date: 2020-11-22 Impact factor: 2.357
Authors: Marc A Miller; David H Adams; Dimosthenis Pandis; Philip M Robson; Amit Pawale; Renata Pyzik; Steve L Liao; Ahmed El-Eshmawi; Percy Boateng; Jalaj Garg; Stephen Waterford; Menachem M Weiner; Srinivas R Dukkipati; Vivek Y Reddy; Zahi A Fayad; Maria G Trivieri Journal: JAMA Cardiol Date: 2020-09-01 Impact factor: 14.676